'House panel weighs new plan for Medicare coverage of Wegovy, cancer blood tests' - Stat News
$CI
$CLOV
$CVS
$EHTH
Medical Specialities
Health Care
Medical Specialities
Health Care
Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 11/18/2024 | $60.00 → $66.00 | Equal Weight → Overweight | Wells Fargo | |
| 11/15/2024 | $1000.00 | Outperform | Wolfe Research | |
| 11/6/2024 | $247.00 → $308.00 | Underperform → Neutral | BofA Securities | |
| 10/17/2024 | Buy → Hold | HSBC Securities | ||
| 10/17/2024 | $1100.00 | Outperform | Bernstein | |
| 10/11/2024 | $675.00 | Overweight | KeyBanc Capital Markets | |
| 10/11/2024 | Sector Weight | KeyBanc Capital Markets | ||
| 10/10/2024 | $63.00 → $82.00 | Equal Weight → Overweight | Barclays |
For Immediate Release: May 31, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA approved mRESVIA (Respiratory Syncytial Virus Vaccine) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. mRESVIA is an mRNA-based vaccine that is manufa
For Immediate Release: May 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA announced a meeting of the Psychopharmacologic Drugs Advisory Committee on June 4 to discuss a new drug application for midomafetamine (MDMA) capsules, submitted by Lykos Therapeutics, for the treatment of post-traumatic stress disorder. The committ
For Immediate Release: March 08, 2024 Today, the U.S. Food and Drug Administration approved a new indication for use for Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight. Wegovy should be used in addition to a reduced calorie diet and increased physical activity. Cardiovascular disease is a gr
SC 13G/A - eHealth, Inc. (0001333493) (Subject)
SC 13G - CVS HEALTH Corp (0000064803) (Subject)
SC 13G/A - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)
CVS Health Board of Directors appoints four new members: Leslie Norwalk, Larry Robbins, Guy Sansone, and Doug Shulman Appointments follow productive engagement with Glenview Capital Management WOONSOCKET, R.I., Nov. 18, 2024 /PRNewswire/ -- The Board of Directors of CVS Health (NYSE:CVS) today announced the appointment of four new board members: Leslie Norwalk, Larry Robbins, Guy Sansone, and Doug Shulman, following productive discussions with Glenview Capital Management. "In our discussions with the leadership at Glenview, we agreed that we can deliver greater value from our
Asha Therapeutics (Asha), a life sciences company pioneering breakthrough therapeutics for neurological disease, announced today the company has been awarded a grant from the ALS Association through its Lawrence and Isabel Barnett Drug Development Program for the advancement of ASHA-624, a novel brain-penetrant intra-molecular glue inhibitor of SARM1. The grant will support the continued development of ASHA-624 towards first-in-human clinical trials as a potential disease-modifying therapeutic for Amyotrophic Lateral Sclerosis (ALS). ASHA-624 was designed using Asha's proprietary PRISM™ drug design technology, which creates new medicines to restore normal biology and provide functional cu
Leading health and well-being company Humana Inc. (NYSE:HUM) announced today that it has named Michelle O'Hara as Chief Human Resources Officer, effective January 1, 2025. O'Hara will oversee the enterprise talent strategy and people programs for Humana's more than 63,000 employees. She brings a proven track record of transforming HR capabilities and enabling companies to effectively attract, recruit, develop and retain a talented and diverse workforce. O'Hara will report directly to Humana President and CEO Jim Rechtin. "Humana's people strategy is a core capability for our business that supports and empowers our workforce so they can successfully deliver on our mission to make it easier
4 - ELI LILLY & Co (0000059478) (Issuer)
4 - ELI LILLY & Co (0000059478) (Issuer)
4 - ELI LILLY & Co (0000059478) (Issuer)
CHICAGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- GoHealth, Inc. (NASDAQ:GOCO) ("GoHealth" or the "Company"), a leading health insurance marketplace and Medicare-focused digital health company, today announced financial results for the three and nine months ended September 30, 2024. Third Quarter Highlights Third quarter 2024 net revenues of $118.3 million, a $13.7 million decrease compared to $132.0 million in the prior year period.Third quarter 2024 Submissions were 166,195, a 2.9% increase compared to 161,550 Submissions in the prior year period, with strong contributions from GoHealth's internal captive agents, partially offset by a decline in Submissions from the external GoPartner Solutio
Delivers 9% Total Revenue growth year-to-date compared to prior year period Company improves 2024 year-to-date GAAP Net Loss from Continuing Operations by $117.4 million year-over-year and year-to-date Adjusted EBITDA by $87.2 million year-over-year Increases Full-Year 2024 guidance midpoint to target updated range of Adjusted EBITDA profitability of $55 million - $65 million, strongly positioning the Company to invest in membership growth opportunity for 2025 FRANKLIN, Tenn., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), today reported financial results for the third quarter 2024. Management will host a co
AUSTIN, Texas, Nov. 6, 2024 /PRNewswire/ -- eHealth, Inc. (NASDAQ:EHTH), a leading private online health insurance marketplace, today announced its financial results for the third quarter ended September 30, 2024. Please click the PDF link to access the full earnings press release: The earnings press release and earnings presentation can also be accessed on the eHealth Investor Relations website at https://ir.ehealthinsurance.com. Webcast and Conference Call InformationA webcast and conference call will be held today, Wednesday, November 6, 2024 at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time. Individuals interested in listening to the conference call ma
Whales with a lot of money to spend have taken a noticeably bearish stance on Novo Nordisk. Looking at options history for Novo Nordisk (NYSE:NVO) we detected 8 trades. If we consider the specifics of each trade, it is accurate to state that 37% of the investors opened trades with bullish expectations and 62% with bearish. From the overall spotted trades, 3 are puts, for a total amount of $155,555 and 5, calls, for a total amount of $255,360. What's The Price Target? Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $100.0 to $175.0 for Novo Nordisk during the past quarter. Analyzing Volume & Open Interest Assessing
Eli Lilly and Co (NYSE:LLY) has outperformed the market over the past 15 years by 11.36% on an annualized basis producing an average annual return of 23.33%. Currently, Eli Lilly and Co has a market capitalization of $730.31 billion. Buying $1000 In LLY: If an investor had bought $1000 of LLY stock 15 years ago, it would be worth $23,116.69 today based on a price of $811.09 for LLY at the time of writing. Eli Lilly and Co's Performance Over Last 15 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automat
8-K - ELI LILLY & Co (0000059478) (Filer)
6-K - NOVO NORDISK A S (0000353278) (Filer)
6-K - NOVO NORDISK A S (0000353278) (Filer)
The recent insider purchase at Clover Health Investments Corp. by Director Garipalli Vivek on June 20, 2024, has caught the attention of investors. Director Garipalli Vivek bought $1,000,426 worth of shares, acquiring 877,567 units at $1.14 per share, as reported in SEC Form 4. This insider purchase stands out among recent insider transactions at Clover Health. Looking at the previous transactions, there have been instances of insiders covering exercise/tax liability by selling shares, resulting in a decrease in their direct ownership percentages. For example, Reynoso Jamie L., Priest Brady Patrick, Toy Andrew, Sharp Aric R, Soares Karen, Chief Technology Officer Wai Conrad, and CEO Reynoso
Wells Fargo upgraded CVS Health from Equal Weight to Overweight and set a new price target of $66.00 from $60.00 previously
Wolfe Research initiated coverage of Eli Lilly with a rating of Outperform and set a new price target of $1,000.00
BofA Securities upgraded Humana from Underperform to Neutral and set a new price target of $308.00 from $247.00 previously
— Lilly to Develop Two Targets Identified and Validated Using Verge Genomics' AI-Enabled, All-in-Human CONVERGE® Platform — Demonstration of the Robust Predictive Power of CONVERGE® - 83% of Prioritized Targets were Validated in Disease-Relevant Models, a Rate Significantly Higher than Industry Standards SOUTH SAN FRANCISCO, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Verge Genomics, a clinical-stage biotechnology company pioneering the use of artificial intelligence (AI) and human data to transform drug discovery and development, announced today that Eli Lilly & Company ("Lilly") (NYSE:LLY) has opted to pursue the development of therapeutics against two validated drug targets for
INDIANAPOLIS, Nov. 19, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it has elected Jon Moeller as a new member of its board of directors, effective Dec. 1, 2024. In addition, the company announced that Karen Walker will transition her role with Lilly, resigning as a member of Lilly's board of directors effective Dec. 31, 2024. In 2025, Ms. Walker will collaborate with Lilly on certain digital commercial activities. Mr. Moeller is the chairman of the board, president and chief executive officer of Procter & Gamble (P&G). A strong leader who has served as an integral part of P&G's leadership team for more than two decades, Mr. Moeller has held key positions withi
WOONSOCKET, R.I., Nov. 19, 2024 /PRNewswire/ -- CVS Health® (NYSE: CVS) today announced that Dr. Sreekanth Chaguturu will be President, Health Care Delivery, in addition to his current role as Executive Vice President and Chief Medical Officer of CVS Health. Dr. Chaguturu replaces Mike Pykosz, who has decided to leave the company. "Sree and I worked closely together when he started at CVS Health, serving as chief medical officer of CVS Caremark. In that role, and as the leader of Medical Affairs at our company, Sree has served as a trusted advisor to our clients, their members
4 - eHealth, Inc. (0001333493) (Issuer)
4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)
4 - eHealth, Inc. (0001333493) (Issuer)